Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?

IF 2 3区医学 Q2 PEDIATRICS BMC Pediatrics Pub Date : 2024-12-23 DOI:10.1186/s12887-024-05327-4

Büşra Tetik Dinçer, Ayşe Merve Usta, Alev Kural, Nazlı Helvacı, Ahmet Uçar, Nafiye Urgancı

{"title":"Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?","authors":"Büşra Tetik Dinçer, Ayşe Merve Usta, Alev Kural, Nazlı Helvacı, Ahmet Uçar, Nafiye Urgancı","doi":"10.1186/s12887-024-05327-4","DOIUrl":null,"url":null,"abstract":"Background: The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that the ongoing low-grade inflammation in obesity and alterations in the enterohepatic axis contributing this process. This study aimed to determine the role of fecal calprotectin (FC) as inflammatory biomarker in obesity and NAFLD.Methods: Between November 2022-August 2023, 31 obese and 10 healthy adolescents aged between 10 and 18 years enrolled in this prospective controlled study. Body mass index higher than 2 standard deviation is considered as obesity. Obese adolescents were divided into two subgroups: obese adolescents (n = 11) and Obese + NAFLD group (n = 20). NAFLD diagnosis was made with biochemical analysis or ultrasonography. FC levels and laboratory parameters analyzed in study group, while only FC samples taken from control group. Anthropometric and laboratory parameters were compared between groups. This study was registered in ClinicalTrials.gov (NCT06229184).Results: The median (IQR P25-75) FC levels in the obese + NAFLD, obese and the healthy controls were 136.23 (43.36-332.04), 61.77 (29.70-285.92) and 38.95 (27.59-50.52) µg/g feces, respectively (p = 0.018). Subgroup analyses revealed that the significant difference was between the obese + NAFLD group and the control group (p = 0.02), while no significant differences were observed between the control and obese groups, or between the obese and obese + NAFLD groups. FC positivity rates were 20% (n = 2) in the control group, 54.5% (n = 6) in the obese group, and 75% (n = 15) in the Obese + NAFLD group (p = 0.018).Conclusions: FC is significantly higher in obese adolescents compared to healthy peers, but no significant difference was observed between obese and obese + NAFLD groups. Further studies needed on this subject.Trial registration: This trial is registered in ClinicalTrials.gov (Trial registration number [ClinicalTrials.gov ID] NCT06229184).","PeriodicalId":9144,"journal":{"name":"BMC Pediatrics","volume":"24 1","pages":"834"},"PeriodicalIF":2.0000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665081/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12887-024-05327-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that the ongoing low-grade inflammation in obesity and alterations in the enterohepatic axis contributing this process. This study aimed to determine the role of fecal calprotectin (FC) as inflammatory biomarker in obesity and NAFLD.

Methods: Between November 2022-August 2023, 31 obese and 10 healthy adolescents aged between 10 and 18 years enrolled in this prospective controlled study. Body mass index higher than 2 standard deviation is considered as obesity. Obese adolescents were divided into two subgroups: obese adolescents (n = 11) and Obese + NAFLD group (n = 20). NAFLD diagnosis was made with biochemical analysis or ultrasonography. FC levels and laboratory parameters analyzed in study group, while only FC samples taken from control group. Anthropometric and laboratory parameters were compared between groups. This study was registered in ClinicalTrials.gov (NCT06229184).

Results: The median (IQR P25-75) FC levels in the obese + NAFLD, obese and the healthy controls were 136.23 (43.36-332.04), 61.77 (29.70-285.92) and 38.95 (27.59-50.52) µg/g feces, respectively (p = 0.018). Subgroup analyses revealed that the significant difference was between the obese + NAFLD group and the control group (p = 0.02), while no significant differences were observed between the control and obese groups, or between the obese and obese + NAFLD groups. FC positivity rates were 20% (n = 2) in the control group, 54.5% (n = 6) in the obese group, and 75% (n = 15) in the Obese + NAFLD group (p = 0.018).

Conclusions: FC is significantly higher in obese adolescents compared to healthy peers, but no significant difference was observed between obese and obese + NAFLD groups. Further studies needed on this subject.

Trial registration: This trial is registered in ClinicalTrials.gov (Trial registration number [ClinicalTrials.gov ID] NCT06229184).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

粪钙保护蛋白可以作为肥胖青少年非酒精性脂肪肝的生物标志物吗？

背景：非酒精性脂肪性肝病（NAFLD）的发病率随着肥胖而增加，人们认为肥胖中持续的低度炎症和肠肝轴的改变促进了这一过程。本研究旨在确定粪便钙保护蛋白（FC）作为炎症生物标志物在肥胖和NAFLD中的作用。方法：在2022年11月至2023年8月期间，31名肥胖青少年和10名年龄在10至18岁之间的健康青少年参加了这项前瞻性对照研究。体重指数高于2个标准差被认为是肥胖。肥胖青少年分为肥胖青少年（n = 11）和肥胖+ NAFLD组（n = 20）两个亚组。通过生化分析或超声检查诊断NAFLD。在研究组中分析FC水平和实验室参数，而在对照组中只分析FC样本。比较两组间的人体测量和实验室参数。该研究已在ClinicalTrials.gov注册（NCT06229184）。结果：肥胖+ NAFLD组、肥胖组和健康对照组中位FC水平（IQR P25-75）分别为136.23（43.36-332.04）、61.77（29.70-285.92）和38.95（27.59-50.52）µg/g粪便（p = 0.018）。亚组分析显示，肥胖+ NAFLD组与对照组之间差异有统计学意义（p = 0.02），而对照组与肥胖组、肥胖组与肥胖+ NAFLD组之间差异无统计学意义。对照组FC阳性率为20% (n = 2)，肥胖组为54.5% (n = 6)，肥胖+ NAFLD组为75% (n = 15) （p = 0.018）。结论：肥胖青少年的FC明显高于健康同龄人，但肥胖组和肥胖+ NAFLD组之间无显著差异。这一问题需要进一步研究。试验注册：本试验已在ClinicalTrials.gov注册（试验注册号[ClinicalTrials.gov ID] NCT06229184）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Pediatrics PEDIATRICS-

CiteScore

3.70

自引率

4.20%

发文量

683

审稿时长

3-8 weeks

期刊介绍： BMC Pediatrics is an open access journal publishing peer-reviewed research articles in all aspects of health care in neonates, children and adolescents, as well as related molecular genetics, pathophysiology, and epidemiology.